EP Wealth Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,275 shares of the biopharmaceutical company’s stock after purchasing an additional 113 shares during the quarter. EP Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,228,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also bought and sold shares of the company. Raymond James & Associates raised its stake in shares of Regeneron Pharmaceuticals by 8.9% in the fourth quarter. Raymond James & Associates now owns 66,999 shares of the biopharmaceutical company’s stock valued at $58,845,000 after acquiring an additional 5,499 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 4.5% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 8,772 shares of the biopharmaceutical company’s stock worth $7,704,000 after buying an additional 381 shares during the period. Pacer Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 15.0% in the 4th quarter. Pacer Advisors Inc. now owns 14,126 shares of the biopharmaceutical company’s stock worth $12,407,000 after buying an additional 1,845 shares during the period. Procyon Advisors LLC increased its stake in Regeneron Pharmaceuticals by 5.7% in the 4th quarter. Procyon Advisors LLC now owns 3,205 shares of the biopharmaceutical company’s stock worth $2,815,000 after buying an additional 174 shares during the period. Finally, Good Life Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $206,000. Institutional investors own 83.31% of the company’s stock.
Insider Buying and Selling
In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on REGN
Regeneron Pharmaceuticals Stock Performance
Shares of NASDAQ:REGN traded up $14.44 during trading on Friday, hitting $1,078.63. 380,897 shares of the stock traded hands, compared to its average volume of 386,591. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The company has a market cap of $118.85 billion, a price-to-earnings ratio of 31.86, a P/E/G ratio of 2.19 and a beta of 0.13. The company has a fifty day moving average price of $1,033.85 and a two-hundred day moving average price of $976.79. Regeneron Pharmaceuticals, Inc. has a 52-week low of $723.56 and a 52-week high of $1,106.16.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.36 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Call Options Volume for These 2 Stocks Spiked Together
- The How And Why of Investing in Oil Stocks
- MarketBeat Week in Review – 7/22 – 7/26
- How to Calculate Options Profits
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.